




[Figure 1]



[Figure 2]



[Figure 3]



[Figure 4]

Amino acid sequence of trastuzumab light chain (SEQ ID NO: 1)

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFGSGRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGGGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDYSLSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of trastuzumab heavy chain (SEQ ID NO: 2)

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGG
PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE
MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRW
QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[Figure 5]

Amino acid sequence of light chain of modified anti-HER2 antibody (SEQ ID NO: 1)

DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPS
RFGSGRSGTDFTLTISSLQPEDFATYYCQQHYYTTPPTFGQGTKVEIKRTVAAPSVFIFPP
SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLT
LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of heavy chain of modified anti-HER2 antibody (SEQ ID NO: 3)

EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRY
ADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLLTVSS
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPEAAG
GPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQY
NSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRE
EMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSR
WQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

(The underline indicates a position of LALA mutation.)

[Figure 6]

(a) Amino acid sequence of wild-type human STING

MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTWGLGEPPEHTLRYLVLHLASLQLGLLL
 NGVCSLAEELRHIHSRYRGSYWRTVRACLGCP LRRGALLLLSIYFYSLPNAVGPPFTWM
 LALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIR
 TYNQHYNLLRGAVSQRLYILLPLDCGVPDNL SMADPNIRFLDKLPQQTGDRAGIKDRVY
 SNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILA
 DAPESQNNCRLIAYQEPADDSSFSLSQEVLRLRQEEKEEVTVGSLKTSAVPSTSTMSQE
 PELLISGMEKPLPLRTDFS

(b) Amino acid sequence of REF-mutated (R232H) human STING

MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTWGLGEPPEHTLRYLVLHLASLQLGLLL
 NGVCSLAEELRHIHSRYRGSYWRTVRACLGCP LRRGALLLLSIYFYSLPNAVGPPFTWM
 LALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIR
 TYNQHYNLLRGAVSQRLYILLPLDCGVPDNL SMADPNIRFLDKLPQQTGDHAGIKDRVY
 SNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILA
 DAPESQNNCRLIAYQEPADDSSFSLSQEVLRLRQEEKEEVTVGSLKTSAVPSTSTMSQE
 PELLISGMEKPLPLRTDFS

(The underline indicates a position of R232H mutation.)


(c) Amino acid sequence of HAQ mutant (R71H, G230A, R293Q) of human STING

MPHSSLHPSIPCPRGHGAQKAALVLLSACLVTWGLGEPPEHTLRYLVLHLASLQLGLLL
 NGVCSLAEELHHIHSRYRGSYWRTVRACLGCP LRRGALLLLSIYFYSLPNAVGPPFTWM
 LALLGLSQALNILLGLKGLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIR
 TYNQHYNLLRGAVSQRLYILLPLDCGVPDNL SMADPNIRFLDKLPQQTADRAGIKDRVY
 SNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCQTLEDILA
 DAPESQNNCRLIAYQEPADDSSFSLSQEVLRLRQEEKEEVTVGSLKTSAVPSTSTMSQE
 PELLISGMEKPLPLRTDFS


(The three underlines indicate positions of R71H mutation, G230A mutation, and R293Q mutation, respectively.)

[Figure 7]


(a)




(b)




[Figure 8]




[Figure 9]




[Figure 10]



[Figure 11]




[Figure 12]




[Figure 13(a)]


(a)




[Figure 13(b)]




[Figure 13(c)]




[Figure 14]



[Figure 15]



[Figure 16]



[Figure 17]

Amino acid sequence of pertuzumab light chain (SEQ ID NO: 28)

DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVP
 RFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGGGTKVEIKRTVAAPSVFIFPP
 SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYLSSTLT
 LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of pertuzumab heavy chain (SEQ ID NO: 29)

EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYTMDWVRQAPGKGLEWVADVPNSGGSIY
 NQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGGGTLTVSSA
 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
 SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
 TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
 TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ
 QGNVFSCSVMEALHNHYTQKSLSLSPGK

[Figure 18]

Amino acid sequence of light chain of modified anti-HER2 antibody 2 (SEQ ID NO: 28)

DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVP
 RFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIKRTVAAPSVFIFPP
 SDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKSTYLSSTLT
 LSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of heavy chain of modified anti-HER2 antibody 2 (SEQ ID NO: 30)

EVQLVESGGGLVQPGGSLRLSCAASGFTFTDYMWDWRQAPGKGLEWVADVNPNSGGSIY
 NQRFKGRFTLSVDRSKNTLYLQMNSLRAEDTAVYYCARNLGPSFYFDYWGQGTLLTVSSA
 STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVTVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGG
 PSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYN
 STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREE
 MTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRW
 QQGNVFSCSVMHEALHNHYTQKSLSLSPGK

(The underlines indicate positions of K214R mutation and LALA mutation.)

[Figure 19]

Amino acid sequence of light chain of anti-CD33 antibody (SEQ ID NO: 31)

DIQLTQSPSTLSASVGDRVITICRASESLDNYGIRFLTWFAQKPGKAPKLLMYAASNQGS
GVPSRFSGSGSGTEFTLTISLQPDDEFATYYCQQTKEVPWSFGQGTKVEVKRTVAAPSVF
IFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSSTYSLS
STLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of heavy chain of anti-CD33 antibody (SEQ ID NO: 32)

EVQLVQSGAEVKKPGSSVKVCKASGYTITDSNIHWVRQAPGQSLEWIGYIYPYNGGTDY
NQKFKNRATLTVDNPTNTAYMELSSLRSEDTAFYYCVNGNPWLAYWGQGLVTVSSASTK
GPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVELTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

[Figure 20]

Amino acid sequence of light chain of anti-EphA2 antibody (SEQ ID NO: 33)

DIVMTQSPLSLPVTGPGEPAISCRSSQSI VHSSGITYLEWYLQKPGQSPQLLIYKVSNRF
SGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQGSHVPYTFGGGTKVEIKRTVAAPSV
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of heavy chain of anti-EphA2 antibody (SEQ ID NO: 34)

QVQLVQSGAEVKKPGASVKVSCKASGYTFIDYSMHWVRQAPGQGLEWMGWINTYTGEPTY
SDDFKGRVTITADTSTSTAYLELSSLRSED TAVYYCATYYRYERDFDYWGQGTLVTVSSA
STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVT VSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS
TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEM
TKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQ
QGNVFSCSVMHEALHNHYTQKSLSLSPGK

[Figure 21]

Amino acid sequence of light chain of anti-CDH6 antibody (SEQ ID NO: 35)

DIQMTQSPSSLSASVGDRVTITCKASQNIYKNLAWYQQKPGKAPKLLIYDANTLQTGVPS
RFSGSGSGSDFTLTISLQPEDFATYFCQQYYSGWAFGQGTKVEIKRTVAAPSVFIFPPS
DEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTL
SKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

Amino acid sequence of heavy chain of anti-CDH6 antibody (SEQ ID NO: 36)

EVQLVQSGAEVKKPGASVKVSCKASGYTFTRNFMHWVRQAPGQGLEWMGWIYPGDGETEY
AQKFQGRVTITADTSTSTAYMELSSLRSED TAVYYCARGVYGGFAGGYFDFWGGGTLTV
SSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAA
GGPSVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQ
YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQPREPQVYTLPPSR
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKS
RWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK

[Figure 22]

